1Brown MA,Kennedy LG,MacGregor AJ,et al.Susceptibility to ankylosing spondylitis in twins:the role of genes,IRA,and the environment[J].Arthritis Rheum,1997,40(10):1823-1828.
4Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis:the bath ankylosing spondylitis disease activity index.J Rheumatol,1994,21(12):2286-2291.
5Critchlow MA, Bland YS. The effect of exogenous Transforming growth factor-beta 2 on healing fractures in the rabbit.Bone,1995,16(5):521.
6Brown MA, Kennedy LG, MacGregor A J, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment [J]. Arthritis Rheum, 1997, 40(10): 1823-1828.
7Braun J, van-der-Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides[J]. Expert Opin Investig Drugs, 2003,12 : 1097-1109.
8Lamhamedi-Cherradi S E,Zheng S,Tisch R M,Chen Y H. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes[J]. Diabetes,2003,52:2274-2278.
9Lub-de-Hooge M N, de-Vries E G, de-Jong, S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus[J]. Ann Rheum Dis,2005,64:854-858.
10Aktas O, Schulze-Topphoff U, Zipp F. The role of TRAIL/TRAIL receptors in central nervous system pathology[J]. Front Biosci, 2007,12 : 2912-2921.
8Chen B, Li D, Xu W. Association of ankylosing spondylitis with HLA B27 and ERAP1 : pathogenic role of antigenic peptide[J]. Med Hypotheses,2013,80(1) :36.
9Robinson PC, Brown MA. The genetics of ankylosing spnndylitis and axiai spondyloarthritis[J]. Rheum Dis Clin North Am, 2012, 38(3) :539.
10Feltkamp TE,Khan MA, Lopez de Castro JA. The pathogenetic role of HLA-B27[J]. Immunol Today, 1996,17 (1) : 5.
